普瑞眼科 reported revenue of ¥1.60B for the period ended 2026-06-30, +9.8% year on year. Net income was ¥0.09B, a 5.8% net margin on a 39.1% gross margin. The largest revenue line is 屈光项目 at 50% of the total. Free cash flow for the period was ¥0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.60B | +9.8% |
| Gross profit | ¥0.63B | — |
| Operating income | ¥0.14B | — |
| Net income | ¥0.09B | +418.5% |
| Gross margin | 39.1% | Net margin 5.8% |
| Revenue Q/Q | -4.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 屈光项目 | ¥0.80B | 50.2% |
| 白内障项目 | ¥0.29B | 18.1% |
| 综合眼病项目 | ¥0.26B | 16.0% |
| 视光项目 | ¥0.22B | 13.7% |
| 其他(补充) | ¥0.03B | 2.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.98B | 60.9% |
| R&D | ¥0.00B | 0.3% |
| SG&A | ¥0.44B | 27.4% |
| Tax & other | ¥0.05B | 2.9% |
| Item | Amount |
|---|---|
| Total assets | ¥4.77B |
| Total liabilities | ¥2.60B |
| Shareholders' equity | ¥2.17B |
| Equity / assets | 45.4% |
| Operating cash flow | ¥0.16B |
| Capital expenditure | ¥0.11B |
| Free cash flow | ¥0.05B |
| Cash conversion (OCF / net income) | 360% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
宏源药业 ・ 杰创智能 ・ 威尔高 ・ 同星科技 ・ 通力科技 ・ 华融化学 ・ 普蕊斯 ・ 富士莱 ・ 艾布鲁 ・ 格力博 ・ 恒工精密 ・ 海看股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies